Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.
News|Articles|April 22, 2020
COVID-19: Quick Self-Check for Health Professionals
Rajesh R. Tampi, MD, MS, DFAPA, provides guidance for frontline health professionals and caregivers to mitigate stress and burden.
Advertisement
Rajesh R. Tampi, MD, MS, DFAPA, provides guidance for frontline health professionals and caregivers to mitigate stress and burden.
Dr Tampi is Chairman, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH, and Chief, Section of Geriatric Psychiatry, and Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH
Advertisement
Related to this article
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
4
New Analyses of HLP003 for the Adjunctive Treatment of MDD
5